Target Corporation (TGT)

Operating Expenses

$25.54B

TTM · Period ending: · USD

TGT logo

TGT Operating Expenses

Latest reported$25.54B
TGT TTM Operating Expenses ($8.16B → $25.54B)
High-resolution chart · PNG

TGT operating expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Target Corporation Operating Expenses — Trailing twelve months (TTM) (USD)
Period endingOperating Expenses (USD)
25,538,000,000
25,153,000,000
24,152,000,000
23,991,000,000
23,931,000,000
23,958,000,000
24,498,000,000
24,580,000,000
24,387,000,000
24,147,000,000
23,969,000,000
23,608,000,000
23,492,000,000
23,288,000,000
23,043,000,000
22,893,000,000
22,513,000,000
22,352,000,000
22,096,000,000
21,974,000,000
21,726,000,000
21,315,000,000
20,845,000,000
19,972,000,000
19,512,000,000
18,983,000,000
18,590,000,000
18,406,000,000
18,145,000,000
18,076,000,000
17,947,000,000
18,045,000,000
17,893,000,000
17,611,000,000
17,365,000,000
17,276,000,000
16,805,000,000
16,432,000,000
16,262,000,000
15,529,000,000
15,982,000,000
16,279,000,000
16,634,000,000
17,000,000,000
16,882,000,000
16,972,000,000
16,805,000,000
15,875,000,000
16,118,000,000
16,222,000,000
16,461,000,000
17,189,000,000
17,013,000,000
16,892,000,000
16,687,000,000
16,725,000,000
16,550,000,000
16,413,000,000
16,237,000,000
16,055,000,000
15,862,000,000
15,639,000,000
15,553,000,000
15,505,000,000
15,419,000,000
15,274,000,000
15,102,000,000
15,471,000,000
15,796,000,000
16,130,000,000
16,389,000,000
16,074,000,000
15,841,000,000
15,550,000,000
15,289,000,000
15,938,000,000
15,594,000,000
15,294,000,000
15,022,000,000
13,942,000,000
13,542,000,000
13,181,000,000
12,982,000,000
12,617,000,000
12,434,000,000
12,026,000,000
11,650,000,000
11,882,000,000
11,546,000,000
11,417,000,000
11,632,000,000
11,165,000,000
11,409,000,000
11,665,000,000
11,393,000,000
11,052,000,000
10,761,000,000
10,350,000,000
9,976,000,000
9,754,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.